EICHORCondition: Cancer · HLA-A*02:01-positive · Sponsor: Immunocore Ltd
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
This description comes directly from the study's public registry record.
Immunocore Medical Information · 844-466-8661 · medical.information@immunocore.com
Immunocore Medical Information EU · +00 800-744-51111 · medinfo.eu@immunocore.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * HLA-A\*02:01-positive * Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma * Archived or fresh tumor tissue sample that must be confirmed as adequate * Evaluable/Measurable disease per RECIST 1.1 * Previously received applicable standard treatments * Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control Exclusion Criteria: * Symptomatic or untreated central nervous system metastasis * Recent bowel obstruction * Ongoing ascites or effusion requiring recent drainages * Significant ongoing toxicity from prior anticancer treatment * Out-of-range laboratory values * Clinically significant lung, heart, or autoimmune disease * Ongoing requirement for immunosuppressive treatment * Significant secondary malignancy * Hypersensitivity to study drug or excipients * Pregnant or lactating
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| St Vincent's Hospital | Darlinghurst, Sydney, Australia | Active Not Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Australia | Recruiting |
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Universitaetsklinikum Heidelberg | Heidelberg, Germany | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma, Italy | Recruiting |
| nstituto Clinico Humanitas | Rozzano, Italy | Recruiting |
| Antoni van Leeuwenhoek | Amsterdam, Netherlands | Recruiting |
| Hospital HM Nou Delfos | Barcelona, Spain | Recruiting |
| VHIO, Vall d'Hebron University Hospital | Barcelona, Spain | Recruiting |
| Centro Integral Oncologico Clara Campal | Madrid, Spain | Recruiting |
+ 1 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06840119